Extension Agreement between Cyclacel Pharmaceuticals, Inc. and Spiro Rombotis (January 2021)
Cyclacel Pharmaceuticals, Inc. and Spiro Rombotis have agreed to extend their existing agreement, originally dated January 1, 2019, through June 30, 2021. This extension is effective as of January 1, 2021. Both parties have confirmed their acceptance of this extension by signing the document. No other terms are changed or specified in this letter.
Exhibit 10.1
CYCLACEL PHARMACEUTICALS, INC.
200 Connell Drive, Suite 1500
Berkeley Heights, NJ 07922
January 14, 2021
Mr. Spiro Rombotis
c/o Cyclacel Pharmaceuticals, Inc.
200 Connell Drive, Suite 1500
Berkeley Heights, NJ 07922
Dear Mr. Rombotis:
Reference is made to the agreement between us (the “Agreement”) made as of January 1, 2019. This will confirm our agreement to extend the Agreement through the period ended June 30, 2021, effective as of January 1, 2021. Please confirm your agreement to the foregoing by signing below in the space provided.
| Sincerely, | ||
| CYCLACEL PHARMACEUTICALS, INC. | ||
| By: | /s/ Paul McBarron | |
| Name: | Paul McBarron | |
| Title: | EVP, Finance & COO | |
| ACKNOWLEDGED AND AGREED: | |
| /s/ Spiro Rombotis | |
| Spiro Rombotis |
